Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Market Perform Rating for Ares Commercial Real Estate with Revised Price Target

Elaine Mendonca by Elaine Mendonca
February 26, 2024
in Breaking News
0
Finance_ Stock Trading (2)
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

On February 26, 2024, Jade Rahmani, an analyst at Keefe, Bruyette & Woods, reaffirmed a Market Perform rating for Ares Commercial Real Estate (NYSE:ACRE) but revised the price target downwards from $10.25 to $8. This change in the price target indicates a shift in Rahmani’s perspective on the company’s performance and worth. Investors should take note of these updates to inform their investment choices.

ACRE Stock Performance Declines on February 26, 2024: What Investors Need to Know

On February 26, 2024, Ares Commercial Real Estate Corporation (ACRE) experienced a decline in its stock performance. Trading near the bottom of its 52-week range and below its 200-day simple moving average, ACRE shares faced challenges in the market.

The price of ACRE shares dropped by $0.33 since the market closed, marking a 4.35% decrease in value. The stock opened at $7.50, which was $0.09 lower than its previous close. This decline in stock price may have been influenced by various factors such as market conditions, industry trends, or company-specific news.

Investors and analysts closely monitor stock performance indicators such as price momentum to gauge the health of a company’s stock. ACRE’s current position below its 200-day simple moving average indicates a bearish trend in the stock’s performance.

For investors considering ACRE as a potential investment opportunity, it is crucial to conduct thorough research and analysis before making any decisions. Understanding the company’s financials, market position, and growth prospects can help investors make informed choices.

While ACRE’s stock performance on February 26, 2024, showed a decline, it is essential to remember that stock prices can fluctuate daily based on various factors. Keeping track of market trends and staying informed about company developments can help investors navigate the stock market effectively.

ACRE Stock Performance Analysis: Modest Revenue Increase but Significant Net Losses

On February 26, 2024, ACRE stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for ACRE stood at $192.08 million for the past year, showing an 11.13% increase compared to the previous year. However, the total revenue remained flat at $47.51 million for the last quarter.

In terms of net income, ACRE reported a net loss of -$38.87 million for the past year, which represents a significant decrease of 230.49% compared to the previous year. The net loss further widened to -$39.41 million for the last quarter, marking a staggering decrease of 529.16% since the previous quarter.

Earnings per share (EPS) for ACRE also showed a downward trend. The EPS was reported at -$0.72 for the past year, reflecting a decrease of 225.31% compared to the previous year. The EPS remained unchanged at -$0.73 for the last quarter, indicating a 0.0% increase since the previous quarter.

Overall, the financial performance of ACRE on February 26, 2024, suggests that while the total revenue saw a modest increase compared to the previous year, the company experienced significant losses in terms of net income. The decrease in earnings per share further highlights the challenges faced by ACRE in maintaining profitability. Investors and analysts will be closely monitoring the company’s future financial reports to assess its ability to turn around its financial performance and achieve sustainable growth in the long term.

Tags: ACRE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Healthcare-and-Tech

Centene NYSECNC A Decade of Strong Financial Performance and Growth

Finance_Assets (3)

Financial Analyst Upgrades Price Target for Newmark Group to 1125

Biopharmaceutical Stock Market Today (1)

GSKs Gepotidacin A Potential Game Changer in the Fight Against Gonorrhea

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com